AKT1 and Hepatic fibrosis: showed that kinsenoside treatment improved the hepatic inflammatory microenvironment of hepatic fibrosis and reprogrammed intracellular glycolysis by inhibiting the migration and maturation of DCs via inhibition of PI3K/AKT signaling (56).